Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC

NCT05718882 · clinicaltrials.gov ↗
NA
Phase
TERMINATED
Status
5
Enrollment
OTHER
Sponsor class

Stopped The study was terminated because the originally planned VIC-1911 dose-escalation scheme (100 mg, 150 mg, 200 mg BID) was scientifically unjustified, lacking prior clinical safety data to support such starting doses when combined with lenvatinib in HC

Conditions

Interventions

Sponsor

RenJi Hospital